M. Marcondes

Wnt / ß-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome

Mathijs, Ahrens, Michael G. Kharas, 2017 .

Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?

H. Deeg, M. Marcondes, 2008, Best practice & research. Clinical haematology.

Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies.

M. Perales, C. Turtle, J. Zalevsky, 2021, Future oncology.

Tumour necrosis factor‐induced gene expression in human marrow stroma: clues to the pathophysiology of MDS?

H. Deeg, J. Radich, D. Stirewalt, 2008, British journal of haematology.

Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).

J. Brugarolas, F. Cattaruzza, J. Zalevsky, 2019, Journal of Clinical Oncology.

Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model

D. Busch, C. Turtle, S. Riddell, 2019, Blood.

Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)

C. Klein, M. Cairo, Dean Anthony Lee, 2020, Blood.